Valneva (NASDAQ:VALN) Sees Large Volume Increase - Here's Why

Key Points

• Valneva (NASDAQ:VALN) experienced a significant increase in trading volume, with 91,610 shares traded, up 45% from the previous session, and the stock price rose to $11.84 from $11.53.
• Guggenheim has decreased its price target for Valneva from $15.00 to $14.00 while maintaining a "buy" rating on the stock.
• Valneva reported a quarterly earnings beat with an EPS of ($0.16), exceeding analysts’ expectations, and generated revenue of $54.84 million, surpassing estimates of $46.28 million.

Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) shares saw unusually-high trading volume on Monday . Approximately 91,610 shares changed hands during trading, an increase of 45% from the previous session's volume of 63,145 shares.The stock last traded at $11.84 and had previously closed at $11.53.

Wall Street Analysts Forecast Growth

VALN has been the subject of several research reports. Guggenheim dropped their price target on Valneva from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, May 8th. HC Wainwright initiated coverage on Valneva in a report on Tuesday. They set a "buy" rating and a $18.00 price target for the company. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $16.00.

Valneva Stock Performance

The stock has a 50 day simple moving average of $7.20 and a 200 day simple moving average of $6.88. The company has a current ratio of 2.27, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. The stock has a market cap of $965.52 million, a P/E ratio of -11.64 and a beta of 1.77.

Valneva (NASDAQ:VALN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.11. Valneva had a negative return on equity of 34.78% and a negative net margin of 33.87%.The firm had revenue of $54.84 million for the quarter, compared to analyst estimates of $46.28 million. On average, equities analysts expect that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current year.

Hedge Funds Weigh In On Valneva

Several hedge funds and other institutional investors have recently modified their holdings of VALN. Wells Fargo & Company MN increased its stake in shares of Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock valued at $1,079,000 after purchasing an additional 30,859 shares during the last quarter. GAMMA Investing LLC bought a new position in shares of Valneva in the 1st quarter valued at $94,000. Frazier Life Sciences Management L.P. bought a new position in shares of Valneva in the 2nd quarter valued at $8,240,000. Finally, Marex Group plc bought a new position in shares of Valneva in the 2nd quarter valued at $64,000. Institutional investors own 11.39% of the company's stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.